P1a/1b, N=1, Terminated, Innovent Biologics (Suzhou) Co. Ltd. | N=124 --> 1 | Trial completion date: May 2024 --> Aug 2023 | Not yet recruiting --> Terminated; Due to the company's development strategy adjustment]
1 year ago
Enrollment change • Trial completion date • Trial termination
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
Despite the excellent efficacy of PD-1 or PD-L1 inhibitors and brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (cHL), some patients (pts) still have disease progression. IBI322 monotherapy showed a promising anti-tumor effectivity with a manageable safety profile in anti-PD-1 or PD-L1 treatment-resistant classical Hodgkin Lymphoma patients. Clinical trial information: NCT04795128 Hodgkin's lymphoma, Resistance, Immune therapy